GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive: At 16–24 days post-BMT, we found no apparent differences in leukaemia cell numbers between Gdpd3+/+ retro-CML-affected and Gdpd3−/− retro-CML-affected mice that had not been treated with dasatinib (Fig. 6b).